e-learning
resources
London 2016
Tuesday, 06.09.2016
Preclinical pharmacology: drug targets and mechanisms of action
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Role of the acetylcholine in the virus-induced bronchoconstriction
Marco Contoli (Ferrara, Italy), Marco Contoli, Andrea Marcellini, Paolo Casolari, Gaetano Caramori, Alberto Papi
Source:
International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Session:
Preclinical pharmacology: drug targets and mechanisms of action
Session type:
Thematic Poster
Number:
4103
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Marco Contoli (Ferrara, Italy), Marco Contoli, Andrea Marcellini, Paolo Casolari, Gaetano Caramori, Alberto Papi. Role of the acetylcholine in the virus-induced bronchoconstriction. Eur Respir J 2016; 48: Suppl. 60, 4103
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Modulation of inflammation by benralizumab in eosinophilic airway disease
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
Cytokine patterns and latent viruses in patients with severe asthma and COPD
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Autoreactivity and inflammatory phenotypes in patients with COPD and bronchial asthma
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016
LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma.
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Investigating the interaction between bronchoconstriction and cough in asthma
Source: International Congress 2016 – Clinical studies in asthma and immunology
Year: 2016
Tiotropium attenuates pulmonary inflammation in a novel mouse smoke RSV re-infection model
Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections
Year: 2014
Pharmacogenetics in severity of bronchial hyperresponsiveness in asthma
Source: Annual Congress 2013 –Genetic factors in airway development and disease
Year: 2013
Adult asthma patients reporting exacerbations triggered by upper airway infection have increased total IgE and sensitization to HDM
Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases
Year: 2014
Features of inflammation in the asthma patients with osmotic airway hyperresponsiveness
Source: International Congress 2015 – New insights into lung disease pathogenesis
Year: 2015
Assessment of sputum prostaglandins and leukotrienes in COPD exacerbations
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Induced sputum and bronchial hyperresponsiveness in COPD patients
Source: International Congress 2014 – Airway biomarkers
Year: 2014
Effects of PKR inhibitor on poly (I:C)-induced exacerbation of severe asthma
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Airway glucose in COPD exacerbations
Source: International Congress 2016 – Clinical and microbiological aspects of infections in COPD patients
Year: 2016
Spectrum of viral pathogens in adults patients with infectious exacerbations of bronchial asthma
Source: Annual Congress 2013 –Viral infections
Year: 2013
Pulmonary response to salbutamol inhalation using dynamic OE-MRI in patients with asthma
Source: Annual Congress 2013 –The different modalities for current imaging and for future issues
Year: 2013
Induced sputum lipid mediators in severe asthma
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016
Characterisation of asthma patients with persistent airflow obstruction
Source: International Congress 2016 – Clinical studies in asthma and immunology
Year: 2016
Species comparison of interleukin-13 induced airway hyperreactivity as model for allergic asthma
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
Airway hyperresponsiveness (AHR) of small airways assessed by impulse oscillation (IOS) in adult asthma
Source: International Congress 2015 – Asthma mechanisms and management
Year: 2015
Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept